Maternal Serum PAPP-A as an Early Marker of Obstetric Complications?

2014 ◽  
Vol 37 (1) ◽  
pp. 33-36 ◽  
Author(s):  
Tommasa Quattrocchi ◽  
Giovanni Baviera ◽  
Teresa Pochiero ◽  
Francesca Basile ◽  
Laura Rizzo ◽  
...  
Keyword(s):  
Gestational Hypertension ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Maternal Serum ◽  
Control Group ◽  
Retrospective Case ◽  
Intrauterine Growth ◽  
Term Delivery ◽  
Adverse Pregnancy ◽  
Control Study

Objective: The aim of this study was to investigate whether low first-trimester PAPP-A levels are associated with an adverse pregnancy outcome. Materials and Methods: A retrospective case-control study was carried out using a Down's syndrome assays database over a 6-year period, between the 8th and 11th week of pregnancy. There were 164 women with PAPP-A multiples of median (MoM) levels <0.3 and 1,640 women with PAPP-A MoM levels ≥0.3 who served as a control group. Outcome measures were the prevalence of miscarriages, gestational hypertension, preeclampsia, pre-term delivery, gestational diabetes and intrauterine growth retardation in both groups. Results: The two groups significantly differed only for miscarriages: 29 (17.7%) vs. 159 (9.7%), p = 0.04, OR 1.7; gestational hypertension: 15 (9.1%) vs. 74 (4.5%), p = 0.02, OR 2.1, and preeclampsia: 9 (5.5%) vs. 29 (1.8%), p = 0.02, OR 2.5. Discussion: Even if in this study the PAPP-A cutoff considered was lower and was assayed in an earlier period compared with other studies, the detection rate for adverse pregnancy outcomes did not improve.

ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome

2013 ◽  
Vol 51 (6) ◽  
Author(s):  
Koen L. Deurloo ◽  
Ingeborg H. Linskens ◽  
Martijn W. Heymans ◽  
Annemieke C. Heijboer ◽  
Marinus A. Blankenstein ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Gestational Hypertension ◽  
Adverse Pregnancy Outcome ◽  
Area Under The Curve ◽  
Roc Curves ◽  
First Trimester ◽  
Maternal Serum ◽  
Retrospective Case ◽  
Screening Performance ◽  
Adverse Pregnancy

AbstractThe aim of the study was to assess the screening performance of first trimester maternal serum measurements of A-disintegrin-and-metalloprotease 12-s (ADAM12s) and placental protein 13 (PP13) for preeclampsia (PE), gestational hypertension (GH) and small-for-gestational-age (SGA) fetuses.In this retrospective case-control study 220 pregnant women were matched for gestational and maternal age at sampling. Results were expressed as multiples of the median (MoM) and compared using Kruskal-Wallis and Mann-Whitney U-test. Screening performance was assessed by receiver operator characteristics (ROC) curves and area under the curve (AUC).Seventeen cases of PE, 30 cases of GH and eight cases of SGA fetuses were matched with 165 controls. ROC-analysis yielded AUCs for ADAM12s and PP13 of 0.63 and 0.59 for PE, 0.68 and 0.57 for GH and 0.59 and 0.62 for SGA, respectively. Combined ADAM12 and PP13 did not improve the AUC value. When the specificity was set at 80%, corresponding detection rate of ADAM12s was 52% for GH.Combined ADAM12s and PP13 measurements do not predict adverse pregnancy outcome, but decreased first trimester ADAM12s levels are associated with GH.

Is ProBNP a New Marker for Predicting Intrauterine Growth Restriction?

2021 ◽  
Vol 225 (02) ◽  
pp. 125-128
Author(s):  
Hasan Eroğlu ◽  
Nazan Vanlı Tonyalı ◽  
Gokcen Orgul ◽  
Derya Biriken ◽  
Aykan Yucel ◽  
...  
Keyword(s):  
Intrauterine Growth Restriction ◽  
Final Analysis ◽  
First Trimester ◽  
Maternal Serum ◽  
Growth Restriction ◽  
Control Group ◽  
Aneuploidy Screening ◽  
Intrauterine Growth ◽  
Potential Marker ◽  
The Mean

Abstract Purpose To evaluate the usability of first-trimester maternal serum ProBNP levels in the prediction of intrauterine growth restriction (IUGR). Methods In this prospective study, blood samples taken from 500 women who applied to our polyclinic for routine serum aneuploidy screening between the 11–14th gestational weeks were centrifuged. The obtained plasma samples were placed in Eppendorf tubes and stored at −80+°C. For the final analysis, first-trimester maternal serum ProBNP levels of 32 women diagnosed with postpartum IUGR and 32 healthy women randomly selected as the control group were compared. FGR was defined as estimated fetal weight below the 10th percentile for the gestational age. Results The mean ProBNP levels were statistically and significantly higher in the women with intrauterine growth restriction (113.73±94.69 vs. 58.33±47.70 pg/mL, p<0.01). At a cut-off level of 50.93, ProBNP accurately predicted occurrence of IUGR (AUC+= 0.794 (95% confidence interval 0.679–0.910), p+= 0.001) with sensitivity and specificity rates of 78.1 and 69.0%, respectively. Conclusion First-trimester serum ProBNP level was significantly higher in women who developed IUGR compared to healthy controls. First-trimester ProBNP level can be used as a potential marker to predict the development of IUGR in pregnant women.

scholarly journals Clinical realization for different types of preeclampsia (results of a double-centre retrospective study)

2021 ◽  
Vol 5 ◽  
pp. 71-79
Author(s):  
K.V. Shchekleina ◽  
◽  
V.Yu. Terekhina ◽  
E.V. Chaban ◽  
M.G. Nikolaeva ◽  
...  
Keyword(s):  
Perinatal Outcomes ◽  
Control Group ◽  
Retrospective Case ◽  
Term Delivery ◽  
Different Types ◽  
Somatic Status ◽  
Status Data ◽  
Reliable Correlation ◽  
Control Study ◽  
In Pregnancy

Aim of study. To determine specific clinical and diagnostic predictors and symptoms of different preeclampsia phenotypes. Material and methods. A double-centre retrospective case-control study was performed including analysis of somatic status data, obstetric and gynaecological history and peculiarities in pregnancy progression and delivery of 373 female patients. The control group was constituted by 200 female subjects whose physiological pregnancy concluded with term delivery. The main group enrolled 173 patients, the course of pregnancy of which was complicated by development of severe preeclampsia (PE) including placental PE (early) – 44 cases (25%) and severe maternal PE (late) – 129 cases (75%). Over 100 potential clinical and anamnestic risk factors for PE, peculiarities in pregnancy progression and delivery outcomes have been analysed. Results. Despite of the similarity between clinical parameters of different PE phenotypes, placental PE (pPE) is characterised by a more significant arterial hypertension (p=0.0311) and proteinuria (p=0.0005) growing over the course of a day. Therewith, a reliable correlation has been established between the level of diastolic blood pressure and proteinuria (OR=0.87; 95% CI 0.77-0.93; p<0.0001). Maternal PE (mPE) is characterised by growth of symptoms within the period of 1-3 weeks. Significantly more frequently, maternal PE is developed against the background of pathological BMI growth (OR=4.1, p=0.105) and gestational diabetes mellitus (OR=3.6; p=0.0432). Perinatal outcomes in pPE are characterised by high rates of stillbirth (22.7%) and fetal growth retardation (82.6%). Conclusion. Placental (early) PE is characterised by a more severe progression with specific clinical and ultrasound predictors, which makes it possible to outline a cohort of females for closer monitoring and preventive procedures.

scholarly journals A COMPARATIVE STUDY OF MATERNAL OUTCOME IN FIRST-TRIMESTER VAGINAL BLEEDING IN THE DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY, SMS MEDICAL COLLEGE, JAIPUR

2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Savita Meena ◽  
Suniti Verma ◽  
R N Sehra ◽  
Suman Choudhary
Keyword(s):  
Gestational Age ◽  
Vaginal Bleeding ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Control Group ◽  
Case Group ◽  
Medical College ◽  
Obstetrics And Gynaecology ◽  
Increased Risk ◽  
Adverse Pregnancy

Background: The outcome of ongoing pregnancies after first trimester vaginal bleeding is of relevance to women and obstetricians for planning antenatal care and clinical interventions in pregnancy. Hence, this study was conducted to identify the risks associated with first trimester bleed which may facilitate decision making regarding mode, place and timing of delivery during management, which may improve maternal and neonatal outcome. Methods: Hospital based comparative prospective study conducted at Department of Obstetrics and Gynaecology, SMS Medical College & associated Hospitals, Jaipur. Results: APH was found in 4 (8.00%) patients of case group and nil in control group. So, APH was found to be more in the case group than control group but was statistically not significant. Pre-eclampsia was found in 4 (8.00%) in case group and 3 (6.00%) in control group with statistically insignificant difference between the two groups.  26 (52.00%) delivered at the gestational age of ?37 weeks, whereas only 8 (16%) of control group delivered at ?37 weeks. So, the gestational age at delivery of control group subjects was found to be higher as compared to case group subjects and the difference was statistically significant (p=0.001). Conclusion: Threatened miscarriage in early pregnancy increases the risk of adverse pregnancy outcome. In our study, these patients were found to be at an increased risk of preterm delivery, PPROM. Keywords: PROM, Miscarriage, Gestational age

597: Maternal serum low PAPP-A in the first trimester is an independent risk factor for adverse pregnancy outcome

2008 ◽  
Vol 199 (6) ◽  
pp. S172
Author(s):  
Markku Ryynanen ◽  
Sini Peuhkurinen ◽  
Mika Gissler ◽  
Jaana Marttala ◽  
Jaakko Ignatius ◽  
...  
Keyword(s):  
Risk Factor ◽  
Pregnancy Outcome ◽  
Independent Risk Factor ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Maternal Serum ◽  
Adverse Pregnancy

507 Decreased first trimester maternal serum PAPP-A is predictive of adverse pregnancy outcome

2001 ◽  
Vol 185 (6) ◽  
pp. S219
Author(s):  
Sigal Heifetz ◽  
Ofer Lehavi ◽  
Yifat Ochshorn ◽  
Mark Evans ◽  
Michael Kupferminc ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Maternal Serum ◽  
Adverse Pregnancy

First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome

2009 ◽  
Vol 29 (6) ◽  
pp. 553-559 ◽  
Author(s):  
Leona C. Y. Poon ◽  
Ekaterina Nekrasova ◽  
Panagiotis Anastassopoulos ◽  
Panagiotis Livanos ◽  
Kypros H. Nicolaides
Keyword(s):  
Matrix Metalloproteinase ◽  
Pregnancy Outcome ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Maternal Serum ◽  
Matrix Metalloproteinase 9 ◽  
Adverse Pregnancy ◽  
Metalloproteinase 9

Placental Growth Factor and Adverse Obstetric Outcomes in a Mixed-Risk Cohort of Women Screened for Preeclampsia in the First Trimester of Pregnancy

2021 ◽  
pp. 1-9
Author(s):  
Charlotte Kvist Ekelund ◽  
Line Rode ◽  
Ann Tabor ◽  
Jon Hyett ◽  
Andrew McLennan
Keyword(s):  
Growth Factor ◽  
Pregnancy Outcomes ◽  
Gestational Hypertension ◽  
Adverse Pregnancy Outcome ◽  
First Trimester ◽  
Placental Growth Factor ◽  
Adverse Pregnancy Outcomes ◽  
Adverse Outcomes ◽  
Obstetric Outcomes ◽  
Adverse Pregnancy

<b><i>Objective:</i></b> The study aimed to investigate the association between placental growth factor (PlGF) and adverse obstetric outcomes in a mixed-risk cohort of pregnant women screened for preeclampsia (PE) in the first trimester. <b><i>Methods:</i></b> We included women with singleton pregnancies screened for PE between April 2014 and September 2016. Outcome data were retrieved from the New South Wales Perinatal Data Collection (NSW PDC) by linkage to the prenatal cohort. Adverse outcomes were defined as spontaneous preterm birth (sPTB) before 37-week gestation, birth weight (BW) below the 3rd centile, PE, gestational hypertension (GH), stillbirth, and neonatal death. <b><i>Results:</i></b> The cohort consisted of 11,758 women. PlGF multiple of the median (MoM) was significantly associated with maternal sociodemographic characteristics (particularly smoking status and parity) and all biomarkers used in the PE first trimester screening model (notably pregnancy-associated plasma protein A MoM and uterine artery pulsatility index [PI] MoM). Low levels of PlGF (&#x3c;0.3 MoM and &#x3c;0.5 MoM) were independently associated with sPTB, low BW, PE, GH, and a composite adverse pregnancy outcome score, with odds ratios between 1.81 and 4.44 on multivariable logistic regression analyses. <b><i>Conclusions:</i></b> Low PlGF MoM levels are independently associated with PE and a range of other adverse pregnancy outcomes. Inclusion of PlGF should be considered in future models screening for adverse pregnancy outcomes in the first trimester.

Sign in / Sign up

Export Citation Format

Share Document